This publication provides an overview of non-pharmacological and pharmacological management strategies for osteoporosis in older people. The authors claim that older patients derive the greatest benefit from a multifactorial and multidisciplinary approach.
This article provides a practical approach to the workup and management of osteoporosis in patients 65 years or older. Recommendations on who to screen; clinical assessment and testing; interpretation of BMD results, how to treat, when to repeat BMD and referral to osteoporosis specialist.
The most serious consequence of osteoporosis is fractures which has serious negative impacts on quality of life and often results in accelerated deterioration and death. Osteoporosis remains frequently underdiagnosed and/or under-treated, particularly in the elderly who are at the greatest risk. The presence of co-morbid medical conditions can be a risk factor for falls and a barrier to osteoporosis care. Elderly patients are more likely to need additional pharmacological therapy to reduce their risk of fractures. This article reviews the current status of osteoporosis management and emphasizes the need to improve care to increase awareness and improve treatment for this high risk group.
This web page outlines the national plan for eye and vision research pertaining to low vision and blindness rehabilitation at the National Eye Institute. it provides background information on low vision and blindness rehabilition, program goals, highlights of revent progress, and their program objectives.
Age related macular degeneration (AMD) accounts for almost 50% of those registered as blind or partially sighted. 1-4 The development of management strategies is limited by the diverse nature of the age related changes and a lack of a clear understanding of the process of visual loss in the elderly. Effective treatment is limited to the management of sub-retinal neovascularisation (SRNV) in selected cases). Despite early expectations that laser treatment might provide significant benefit in preventing blindness 5-7 recurrent disease and progressive visual failure limit the final outcome. 8-9. Early recognition and prevention of potential disease is not as yet applicable to disease other than that related to SRNV.